What is Lunit?
Lunit is at the forefront of making data-driven medicine the global standard, with a particular focus on combating cancer. The company develops sophisticated AI solutions designed for precision diagnostics and therapeutics. By leveraging artificial intelligence, Lunit aims to provide accurate diagnoses at optimal costs and tailor the most effective treatments for individual patients, thereby addressing critical unmet needs in oncology.
How much funding has Lunit raised?
Lunit has raised a total of $307.5M across 5 funding rounds:
Series A
$3.5M
Series B
$15M
Series C
$78M
Other Financing Round
$61M
Other Financing Round
$150M
Series A (2016): $3.5M, investors not publicly disclosed
Series B (2018): $15M led by SOFTBANK Korea Co., Mirae Asset Global Investments, Capital Intervest, Legend Capital, Kakao Ventures, and KT
Series C (2021): $78M supported by IMM Investment, Guardant Health, Shinhan Investment, Kakao Ventures, InterVest, and Legend Capital
Other Financing Round (2021): $61M featuring BrightEdge, Casdin Capital, and HealthQuest Capital
Other Financing Round (2023): $150M, investors not publicly disclosed
Key Investors in Lunit
HealthQuest Capital
HealthQuest Capital is an investment firm focused on the healthcare sector, likely backing companies that are developing innovative solutions to improve patient outcomes and reduce healthcare costs.
Guardant Health
Guardant Health, founded in 2012, is a leader in cancer diagnostics, offering advanced testing services that help physicians identify treatment alternatives for cancer patients. Their investment in Lunit suggests a strategic alignment in the fight against cancer through precision medicine.
Kakao Ventures
Kakao Ventures is a venture capital firm that invests in technology and innovation. Their participation in Lunit's funding rounds indicates a belief in the company's AI-driven approach to healthcare and its potential for significant market impact.
What's next for Lunit?
The substantial enterprise-level backing and recent strategic investment position Lunit for accelerated growth and innovation. This infusion of capital is expected to fuel further research and development in AI-powered medical imaging and pathology, enabling the company to expand its market reach and enhance its product offerings. Lunit's strategic focus on conquering cancer through advanced AI suggests a trajectory aimed at becoming a leader in precision oncology, potentially leading to further strategic partnerships and market penetration.
See full Lunit company page
